Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that Seattle Genetics’ management will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the “Investor and News” section.

Morgan Stanley Global Healthcare Unplugged Conference

Tuesday, September 14, 2010
3:20 p.m. Eastern Time (ET)
New York, NY
 

Stifel Nicolaus Healthcare Conference 2010

Thursday, September 16, 2010
2:40 p.m. ET
Boston, MA
 

UBS Global Life Sciences Conference

Tuesday, September 21, 2010
2:30 p.m. ET
New York, NY

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the U.S. Food and Drug Administration. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has five other clinical-stage programs: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70, SGN-75 and ASG-5ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as an ADC co-development agreement with Agensys, an affiliate of Astellas. More information can be found at www.seattlegenetics.com.



CONTACT:

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]

KEYWORDS:   United States  North America  Massachusetts  New York  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.